Table 2 Characteristics of the included studies.
Reference | Study details | Patient characteristic | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Study name | Trial number | Type of Study | Timing of Study | Treatment | Definition of POD24 | Median follow-up (month) | Sample size | Median age | Median prior line | Advance stage (%) | POD24 (%) | Refractory to last-line treatment (%) | Prior HSCT (%) | Prior CAR-T (%) | ≥3 prior lines of therapy (%) | High risk FLIPI (%) | Bulky disease (GELF) (%) |
ELARA Fowler et al. [17] | NCT03568461 | Phase 2, Prospective, Multicentre | 2018–2020 | Tisagenlecleucel | Disease progression within 24 months from initiation of a first-line anti-CD20 mAb-containing treatment | 28.9 | 97 | 57 | 4 | 86 | 63 | 78 | 36 | NA | 75 | 60 | 64 |
ZUMA-5 | NCT03105336 | Phase 2, Prospective, Multicentre | 2017–2020 | Axicabtagene ciloleucel | 24 months from initiation of the first line of anti-CD20 containing immunochemotherapy to disease progression | 41.7 | 124 | 60 | 3 | 85 | 55 | 68 | 24 | NA | 63 | 44 | 52 |
TRANSCEND FL Morschhauser et al. [7] | NCT04245839 | Phase 2, Prospective, Multicentre | 2020–2023 | Lisocabtagene maraleucel | Progression of disease within 24 months of diagnosis after treatment with an anti-CD20 antibody and alkylator within 6 months of initial FL diagnosis. | 18.9 | 101 | 62 | 3 | 88 | 43 | 64 | 31 | NA | 55 | 57 | 53 |
RELIANCE Ying et al. [37] | NCT04089215 | Phase 1/2, Prospective, Multicentre | 2019–2024 | Relmacabtagene autoleucel | NA | 11.7 | 28 | 54 | 3 | Not reported | 54 | 64 | Not reported | NA | 67 | Not reported | 25 |
Hirayama et al. [18] | NCT01865617 | Phase 1 /2 Prospective, Single centre | Not reported | CD19 41BB CD4:CD8 ratio 1:1 | NA | 24 | 8 | 53 | 4 | 75 | Not reported | 75 | 50 | NA | 88 (4L+) | 50 | 25 |
Schuster et al. [19] | NCT02030834 | Case-series, Prospective, Single centre | 2014–2016 | CTL019 | NA | 28.6 | 14 | 59 | 5 | 86 | Not reported | Not reported | 28 | NA | Not reported | Not reported | Not reported |
Fried et al. [21] | NCT02772198 | Phase 1b/2, Prospective, Single centre | 2017–2022 | FMC63-derived single-chain fragment variable, CD28, CD19 CAR | Progression of disease within 24 months of first chemoimmunotherapy | 15.4 | 26 | 62 | 3 | 85 | 77 | Not reported | 19 | NA | 27 (4L+) | 77 | 12 |
ELM-1 Bennerji et al. [22] | NCT02290951 | Phase 1, Prospective, Multicentre | 2015–2021 | Odronextamab | NA | 4.2 | 32 | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | 10% | Not reported | Not reported | Not reported |
ELM-2 Kim et al. [10] | NCT03888105 | Phase 2, Prospective, Multicentre | 2019–2022 | Odronextamab | Progression of disease within 24 months of first-line treatment | 20.1 | 128 | 61 | 3 | 85 | 49 | 72 | 30 | 0% | 53.9 | 58 | 14 |
EPCORE NHL-1 Linton et al. [9] | NCT03625037 | Phase 1/2, Prospective, Multicentre | 2020–2023 | Epcoritamab | Progression within 24 months of initiating any first-line therapy | 17.4 | 128 | 65 | 3 | 85 | 52 | 69 | Not reported | 5% | 63 | 61 | 26 |
Budde et al. [23] | NCT02500407 | Phase 2, Prospective, Multicentre | 2019–2021 | Mosunetuzumab | Progression of disease within 24 months after the start of first-line therapy. | 18.3 | 90 | 60 | 3 | 77 | 52 | 69 | 21 | 3% | 62 | 44 | 34 |
FLMOON-01, 2025 Goto et al. [24] | J040295 | Phase 1, Prospective, Multicentre | Not reported | Mosunetuzumab | Disease progression within 24 months from the start of initial therapy | 8 | 19 | 72 | 3 | 84 | 26 | NA | NA | 5% | 63 | 63 | 32 |
